Brian P. Hobbs

Brian P. Hobbs

Auto-generated profile, based on publicly available information

Brian P. Hobbs

Dell Medical School The University of Texas at Austin Austin Texas USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AKAlok A. Khorana
Alok A. Khorana
KTKatherine Tullio
Katherine Tullio
PEPaul Elson
Paul Elson
NPNathan A. Pennell
Nathan A. Pennell
SGStephen R. Grobmyer
Stephen R. Grobmyer
BBBrian J. Bolwell
Brian J. Bolwell
Delays in time to treatment initiation (TTI) for new cancer diagnoses cause patient distress and may adversely affect outcomes. We investigated trends in TTI for common solid tumors treated with curative intent, determinants of increased TTI and association with overall survival. We utilized prospective data from the National Cancer Database for newly diagnosed United States patients with early-stage breast, prostate, lung, colorectal, renal and pancreas cancers from 2004–13. TTI was defined as days from diagnosis to first treatment (surgery, systemic or radiation therapy). Negative binomial regression and Cox proportional hazard models were used for analysis. The study population of 3,672,561 patients included breast (N = 1,368,024), prostate (N = 944,246), colorectal (N = 662,094), non-small cell lung (N = 363,863), renal (N = 262,915) and pancreas (N = 71,419) cancers. Median TTI increased from 21 to 29 days (P<0.001). Aside from year of diagnosis, determinants of increased TTI included care at academic center, race, education, prior history of cancer, transfer of facility, comorbidities and age. Increased TTI was associated with worsened survival for stages I and II breast, lung, renal and pancreas cancers, and stage I colorectal cancers, with hazard ratios ranging from 1.005 (95% confidence intervals [CI] 1.002–1.008) to 1.030 (95% CI 1.025–1.035) per week of increased TTI. TTI has lengthened significantly and is associated with absolute increased risk of mortality ranging from 1.2–3.2% per week in curative settings such as early-stage breast, lung, renal and pancreas cancers. Studies of interventions to ease navigation and reduce barriers are warranted to diminish potential harm to patients.

1 April 2021 in Med
Verified
Journal Article
Closed access
JRJoanna Roopkumar
Joanna Roopkumar
SSShadi Swaidani
Shadi Swaidani
AKAnn S. Kim
Ann S. Kim
BTBicky Thapa
Bicky Thapa
LGLorenzo Gervaso
Lorenzo Gervaso
AKAlok A. Khorana
Alok A. Khorana

8 July 2018 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
BHBrian P. Hobbs
Brian P. Hobbs
RLRick Landin
Rick Landin

12 November 2020 in Blood
Verified
Journal Article
Open access
PDF file
YNYasunobu Nagata
Yasunobu Nagata
RZRan Zhao
Ran Zhao
HAHassan Awada
Hassan Awada
CKCassandra M. Kerr
Cassandra M. Kerr
IMInom Mirzaev
Inom Mirzaev
JMJaroslaw P. Maciejewski
Jaroslaw P. Maciejewski
Morphologic interpretation is the standard in diagnosing myelodysplastic syndrome (MDS), but it has limitations, such as varying reliability in pathologic evaluation and lack of integration with genetic data. Somatic events shape morphologic features, but the complexity of morphologic and genetic changes makes clear associations challenging. This article interrogates novel clinical subtypes of MDS using a machine-learning technique devised to identify patterns of cooccurrence among morphologic features and genomic events. We sequenced 1079 MDS patients and analyzed bone marrow morphologic alterations and other clinical features. A total of 1929 somatic mutations were identified. Five distinct morphologic profiles with unique clinical characteristics were defined. Seventy-seven percent of higher-risk patients clustered in profile 1. All lower-risk (LR) patients clustered into the remaining 4 profiles: profile 2 was characterized by pancytopenia, profile 3 by monocytosis, profile 4 by elevated megakaryocytes, and profile 5 by erythroid dysplasia. These profiles could also separate patients with different prognoses. LR MDS patients were classified into 8 genetic signatures (eg, signature A had TET2 mutations, signature B had both TET2 and SRSF2 mutations, and signature G had SF3B1 mutations), demonstrating association with specific morphologic profiles. Six morphologic profiles/genetic signature associations were confirmed in a separate analysis of an independent cohort. Our study demonstrates that nonrandom or even pathognomonic relationships between morphology and genotype to define clinical features can be identified. This is the first comprehensive implementation of machine-learning algorithms to elucidate potential intrinsic interdependencies among genetic lesions, morphologies, and clinical prognostic in attributes of MDS.

20 October 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BHBrian P. Hobbs
Brian P. Hobbs
RPRoberto Carmagnani Pestana
Roberto Carmagnani Pestana
EZEmily C. Zabor
Emily C. Zabor
AKAlexander M. Kaizer
Alexander M. Kaizer
DHDavid S. Hong
David S. Hong
Advances in biology and immunology have elucidated genetic and immunologic origins of cancer. Innovations in sequencing technologies revealed that distinct cancer histologies shared common genetic and immune phenotypic traits. Pharmacologic developments made it possible to target these alterations, yielding novel classes of targeted agents whose therapeutic potential span multiple tumor types. Basket trials, one type of master protocol, emerged as a tool for evaluating biomarker-targeted therapies among multiple tumor histologies. Conventionally conducted within the phase II setting and designed to estimate high and durable objective responses, basket trials pose challenges to statistical design and interpretation of results. This article reviews basket trials implemented in oncology studies and discusses issues related to their statistical design and analysis.

3 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
XWXin Wang
Xin Wang
NPNicolas Palaskas
Nicolas Palaskas
BHBrian P. Hobbs
Brian P. Hobbs
JAJun-ichi Abe
Jun-ichi Abe
KNKevin T Nead
Kevin T Nead
SLSteven Lin
Steven Lin
Background: There is a paucity of data regarding the association between radiation exposure of heart substructures and the incidence of major coronary events (MCEs) in patients with esophageal cancer (ESOC) undergoing chemoradiation therapy. We studied radiation dosimetric determinants of MCE risk and measured their impact on patient prognosis using a cohort of ESOC patients treated at a single institution. Methods: Between March 2005 and October 2015, 355 ESOC patients treated with concurrent chemoradiotherapy were identified from a prospectively maintained and institutional-regulatory-board-approved clinical database. Dose-distribution parameters of the whole heart, the atria, the ventricles, the left main coronary artery, and three main coronary arteries were extracted for analysis. Results: Within a median follow-up time of 67 months, 14 patients experienced MCEs at a median of 16 months. The incidence of MCEs was significantly associated with the left anterior descending coronary artery (LAD) receiving ≥30 Gy (V30Gy) (p = 0.048). Patients receiving LAD V30Gy ≥ 10% of volume experienced a higher incidence of MCEs versus the LAD V30Gy < 10% group (p = 0.044). The relative rate of death increased with the left main coronary artery (LMA) mean dose (Gy) (p = 0.002). Furthermore, a mutual promotion effect of hyperlipidemia and RT on MCEs was observed. Conclusion: Radiation dose to coronary substructures is associated with MCEs and overall survival in patients with ESOC. In this study, the doses to these substructures appeared to be better predictors of toxicity outcomes than mean heart dose (MHD) or whole-heart V30Gy. These findings have implications for reducing coronary events through radiation therapy planning.